若生智能
Drug Database
TR

travoprost + timolol (TTFC, Alcon / TTFC, Alcon)

✓ Approved

Novartis AG · ADRB1 · 小分子

什么是 travoprost + timolol？

travoprost + timolol 是一种小分子，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名TTFC, Alcon, TTFC, Alcon
公司Novartis AG
药物类别小分子
分子靶点ADRB1, ADRB2, PTGFR
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Novartis AG

作用机制

分子靶点

travoprost + timolol 作用于 3 个分子靶点：

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (ADRBR, B2AR)
PTGFRprostaglandin F receptor (FP)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

travoprost + timolol 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersGlaucoma✓ Approved

相关研究文献

PubMedJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2026-08-03

Sustained-Release Intracameral Prostaglandin Analog Implants for Glaucoma: Comparative Review and Meta-Analysis of Bimatoprost and Travoprost Delivery Systems.

Chopra Alexander L AL, Siringoringo Clyde C, Siu Sharmayne S, Francis Brian B et al.

To evaluate the efficacy and safety of sustained-release intracameral prostaglandin analog implants, including bimatoprost (Durysta) and travoprost (iDose TR), in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A systematic review and pooled quantitative analysis were performed according to PRISMA guidelines. PubMed, Scopus, Embase, and Google Scholar were searched for studies published between 2020 and 2025 evaluating sustained-release intracameral prostaglandin implants. Randomized and nonrandomized studies reporting intraocular pressure (IOP) and safety outcomes were included. Six studies comprising 1,047 eyes met inclusion criteria. Bimatoprost implants (10 µg and 15 µg) achieved mean IOP reductions of 6.1-6.7 mmHg at 12 months, whereas pooled slow-eluting travoprost implant data demonstrated reductions ranging from 5.5 to 7.75 mmHg depending on study design and follow-up duration. Subgroup analysis demonstrated comparable efficacy between travoprost and bimatoprost implants at 3 months; however, at 12 months, travoprost efficacy was lower than the 15 µg bimatoprost implant while remaining comparable to the 10 µg implant. Most adverse events were mild and transient. Corneal endothelial cell loss occurred in a dose-dependent manner with repeated bimatoprost administrations, particularly with the 15 µg implant, whereas no significant endothelial cell loss was reported with travoprost implants. Both implants substantially reduced topical medication burden. Sustained-release intracameral prostaglandin implants provide durable IOP reduction while decreasing dependence on topical therapy. Although efficacy differences between travoprost and bimatoprost implants appear modest, their safety profiles differ, particularly regarding corneal endothelial effects. Further long-term comparative studies are warranted.

PMID 42544565
阅读全文 →
PubMedCase reports in ophthalmological medicine2026-07-31

Choroidal Detachment in a Patient on a CPAP Therapy.

Żurowska Emilia E, Zwolińska Emilia E, Rospond-Kubiak Iwona I

The aim of the study is to present a rare case of choroidal detachment in a patient on continuous positive airway pressure (CPAP) therapy. A 76-year-old man on CPAP therapy due to obstructive sleep apnea presented to the ocular oncology clinic with a suspicion of an intraocular tumor. He complained of tunnel vision in red, floaters and flashes in the visual field, and irritation of the left eye since 13 weeks. On initial assessment, the best corrected visual acuity (BCVA) of the left eye was 1.0, and the intraocular pressure (IOP) was 21 mmHg. The examination revealed dilated, tortuous episcleral vessels and a massive choroidal effusion. The patient was diagnosed with choroidal detachment and was treated with topical dexamethasone 0.1% and cyclopentolate. On a follow-up visit 3 weeks later, the BCVA got worse to hand movements and IOP increased to 27 mmHg. The patient received a combination of dorzolamide and timolol in addition to the aforementioned treatment. Over the following 16 weeks, a gradual resolution of the choroidal detachment was documented. The CPAP treatment is a possible, though unproven, contributor to the choroidal detachment. The patient improved during corticosteroid, cycloplegic, and IOP-lowering treatment.

PMID 42534308
阅读全文 →
PubMedOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde2026-07-29

Quantifying Phacoemulsification Handpiece Repulsion as a Function of Tip Design: A Particle Image Velocimetry Study.

Rossi Tommaso T, Querzoli Giorgio G, Pellizzaro Camilla C, Rosari Giulia G et al.

To compare the fluidics of different phaco tip designs: straight, flared and balanced, across 2 orthogonal planes centred on tip aperture, at the aim of inferring lens fragments attraction and repulsion determined by sheer fluid motion. Phaco handpiece of Virtuoso (BVI), longitudinally drove straight and flared tips, while Centurion (Alcon), drove balanced tip in longitudinal, torsional, and combined modes. Tests were run into a Plexiglas chamber filled with Balanced Salt Solution with neutrally buoyant particles and Particle Image Velocimetry analysis performed at 6,250 frames per second. BSS velocity increased with stroke length and was significantly higher for the balanced tip longitudinal stroke (p<0.01). At 90% ultrasound power, the balanced tip generated significantly higher BSS velocities than the straight and flared tips, both in longitudinal, purely torsional, and combined motion (p<0.05). Aspiration significantly altered BSS velocities in all tested tips (p<0.05 for all), increasing attraction. Straight tips showed the lowest BSS velocity at all stroke lengths (p<0.01); balanced tip in torsional mode had the second highest BSS velocity (after the same tip in longitudinal mode) across the vertical plane. Straight tips in longitudinal mode determine significantly lower fluid velocity in a test chamber than flared and balanced tips operating in longitudinal, torsional, and combined mode.

PMID 42525583
阅读全文 →
PubMedPharmaceutics2026-07-28

Punctal and Intracanalicular Drug Delivery Systems for Ophthalmic Use: A Narrative Review of Technologies, Clinical Outcomes, and Critical Quality Attributes.

Bakhrushina Elena O EO, Leonova Kseniia S KS, Belyavsky Nikita O NO, Gegechkori Vladimir I VI et al.

Background: Conventional ophthalmic eye drops have low bioavailability (<5%) and poor patient adherence, driving the development of sustained-release ophthalmic drug delivery systems. The lacrimal drainage system represents a unique anatomical site for minimally invasive depot formulations. Objective: To summarize and critically appraise punctal and intracanalicular drug delivery systems, occlusive devices, and in situ-forming hydrogels with respect to composition, release mechanisms, clinical efficacy, safety, and critical quality attributes (CQAs). Methods: A narrative literature review was conducted using PubMed, Scopus, Web of Science, Google Scholar, ClinicalTrials.gov, and patent/regulatory sources, including FDA materials and Google Patents, covering 2001-2026. Anatomical features, materials, active pharmaceutical ingredients, release profiles, and adverse events were analyzed. Results: Seventy-one sources were included. Occlusive plugs without an active pharmaceutical ingredient demonstrate premature expulsion in up to 57.4% of cases and bacterial colonization in 44%. Drug delivery systems provide release from 7 days (PEGDA hydrogels) to 3 months (Eximore, Ocular Therapeutix™). DEXTENZA® (dexamethasone) is FDA-approved for postoperative inflammation, whereas pivotal trials of travoprost (OTX-TP) and latanoprost systems (L-PPDS, EXP-LP) did not demonstrate superiority over placebo or eye drops. In situ systems eliminate size-fitting requirements but face challenges related to gelation control and biodegradation. Conclusions: We propose the following candidate CQAs: retention (>80% over 4 weeks), swelling degree (30-60%), controlled burst release (<40% within 24 h), and mechanical compatibility. The proposed QTPP matrices for punctal, intracanalicular, and in situ systems may guide the development of ophthalmic drug delivery platforms.

PMID 42514908
阅读全文 →
PubMedOphthalmology and therapy2026-07-25

Extended Depth of Field Intraocular Lens for Cataract After Vitrectomy for Retinal Detachment: A Prospective Trial.

Vounotrypidis Efstathios E, Begaj Dorian D, Kamnig Rupert R, Meyer Julie J et al.

This study aimed to evaluate visual outcomes and patient satisfaction following implantation of a non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) in eyes with cataract developing after pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD). Patients who underwent PPV for RRD, with or without macular involvement, and subsequently developed cataract were prospectively enrolled. Cataract surgery was performed with implantation of the Vivity EDOF-IOL (Alcon). Bilateral implantation was performed according to patient preference. Inclusion criteria were attached retina 3-6 months after PPV and corrected distant visual acuity of 0.3-0.7 logMAR. Primary outcomes were monocular and binocular, corrected and uncorrected distance, intermediate, and near visual acuity (CDVA, UDVA, DCIVA, UIVA, DCNVA, UNVA) at 6 months. Secondary outcomes included defocus curve and patient-reported satisfaction. Twenty-seven patients (43 eyes) underwent surgery at 6 ± 3 months after PPV (16 patients bilateral). Thirteen patients had RRD with macular involvement. In the RRD-affected eyes CDVA improved statistically significantly from 0.35 ± 0.16 to 0.03 ± 0.12 and UDVA from 1.01 ± 0.34 to 0.16 ± 0.19 logMAR at 6 months. Mean visual acuities at 6 months for RRD-affected eyes were DCIVA 0.53 ± 0.21, UIVA 0.44 ± 0.15, DCNVA 0.59 ± 0.23, and UNVA 0.47 ± 0.23 logMAR. Binocular UDVA, UIVA, and UNVA for the bilateral cases were - 0.04 ± 0.11, 0.29 ± 0.10, and 0.26 ± 0.13 logMAR, respectively. The defocus curve was comparable between macula-on, macula-off, and fellow eyes. Patient satisfaction was favorable with just two patients reporting halos. Using the Vivity EDOF-IOL in selected patients with cataract after successful PPV for RRD appears to be a safe and effective option, yielding favorable visual outcomes regardless of macular involvement. DRKS00037029.

PMID 42501215
阅读全文 →
PubMedPediatric dermatology2026-07-24

A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations.

Fason Claire C, Jafari Alexander J AJ, Hebert Adelaide A AA

Dermatologists play a central role in the diagnosis and medical management of vascular anomalies. Currently, vascular anomalies are categorized into vascular tumors and vascular malformations. The latest designations for the numerous types of vascular lesions are delineated in the International Society for the Study of Vascular Anomalies website (www.issva.org). The arenas for the therapy for hemangiomas, the most common vascular tumor, have been studied extensively and have been recognized as standard of care by the Society for Pediatric Dermatology, the American Academy of Dermatology and the American Academy of Pediatrics. Options for hemangioma treatment include systemic beta-blockers such as propranolol, atenolol, and nadolol, and the topical beta-blocker timolol. Vascular malformations and overgrowth syndromes encompass a separate set of treatment regimens. Recent pharmacological and technological advances in the medical management of vascular anomalies have decreased the need for surgery in many patients while also leading to improved outcomes and quality of life. This review will guide the dermatologist through the current medical treatment landscape for vascular malformations.

PMID 42492908
阅读全文 →

注册免费账户还可查看另外 7318 篇文献

免费注册查看全部文献 →

了解更多travoprost + timolol